Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 17, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].

Hirokazu Watanabe1, Morihito Okada, Yasushi Kaji

  • 1Division of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 17, 2009
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and Imaging Features of Tepotinib-Induced Interstitial Lung Disease in the Post-Marketing Setting in Japan.

Cancer science·2026
Same author

Correction to: Deep learning-based motion correction: cardiac motion artifact and image quality improvements on chest CT.

Japanese journal of radiology·2026
Same author

Pulmonary Collision Tumor Comprising Lung Adenocarcinoma and Metastatic Endometrial Cancer: A Case Report.

Thoracic cancer·2026
Same author

Deep learning-based motion correction: cardiac motion artifact and image quality improvements on chest CT.

Japanese journal of radiology·2026
Same author

Histological Features of Lung Squamous Cell Carcinoma According to Radiological Early-Phase Progression Patterns.

Pathology international·2026
Same author

Systemic-airway eosinophil discordance and sputum mediator profiling in severe asthma treated with biologics: a retrospective cohort study.

BMC pulmonary medicine·2026

This study overviews the revised Response Evaluation Criteria In Solid Tumours (RECIST) guideline, version 1.1. It focuses on the updated content for evaluating cancer treatment response.

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Radiology

Background:

  • Standardized criteria are essential for evaluating cancer treatment efficacy.
  • The original RECIST guideline (version 1.0) provided a framework for response assessment.
  • Limitations in RECIST 1.0 necessitated updates for improved accuracy and consistency.

Purpose of the Study:

  • To provide a comprehensive overview of the revised RECIST guideline (version 1.1).
  • To highlight the key updates and changes incorporated into RECIST 1.1.
  • To facilitate consistent application of the new criteria in clinical practice and research.

Main Methods:

  • Review of the official RECIST 1.1 documentation.
  • Comparative analysis of RECIST 1.1 against RECIST 1.0.

Related Experiment Videos

Last Updated: Jun 17, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

  • Identification and explanation of significant modifications in assessment methodology.

    • Main Results:

    • RECIST 1.1 introduces refined definitions for target and non-target lesions.
    • New criteria for complete response, partial response, stable disease, and progressive disease are detailed.
    • Updated methodologies for measuring lesions and assessing overall response are presented.

    Conclusions:

    • RECIST 1.1 offers enhanced precision in evaluating solid tumour response to therapy.
    • Adoption of RECIST 1.1 is expected to improve the reliability of clinical trial outcomes.
    • Understanding these revisions is crucial for oncologists, radiologists, and researchers.